Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Triple Negative Breast Neoplasms 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Neoplasm Metastasis 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Composite Lymphoma 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Cyclophosphamide 176Rituximab 164fludarabine phosphate 97Peripheral Blood Stem Cell Transplantation 95Filgrastim 73Etoposide 67Radiotherapy 63Mycophenolic Acid 62Whole-Body Irradiation 58Tacrolimus 49Melphalan 49Cyclosporine 49Busulfan 47Lenalidomide 45Antilymphocyte Serum 39Vincristine 37Prednisone 37Cytarabine 37fludarabine 35Methotrexate 33Carmustine 32obinutuzumab 31Doxorubicin 30Bendamustine Hydrochloride 30Methylprednisolone 27ibritumomab tiuxetan 25Cord Blood Stem Cell Transplantation 25sargramostim 24Bortezomib 24Granulocyte Colony-Stimulating Factor 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Lymphoma, Follicular × ALX148 × Clear all
NCT05025800 2026-03-20

ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
47 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Composite Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡